<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596557</url>
  </required_header>
  <id_info>
    <org_study_id>004765</org_study_id>
    <nct_id>NCT00596557</nct_id>
  </id_info>
  <brief_title>Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up</brief_title>
  <acronym>CRAD001AILO2</acronym>
  <official_title>Phase IV: Effect of Everolimus and CNI Minimalization on Renal Function.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The different mechanisms of action of Everolimus and cyclosporine suppress immune function in&#xD;
      synergistic manner. Thus it is postulated that the use of Everolimus in combination with&#xD;
      cyclosporine permits a significant cyclosporine dose reduction without loss of&#xD;
      immunosuppressive activity in the clinical setting.&#xD;
&#xD;
      The aim of the present study is to evaluate the evolution of renal function after initiation&#xD;
      of Everolimus and minimalisation of CNI dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Everolimus is a new proliferation signal inhibitor with immunosuppressive and&#xD;
      antiproliferative activity.&#xD;
&#xD;
      The mechanism of action of Everolimus is distinct from that of calcineurin inhibitors.&#xD;
&#xD;
      Cardiac allograft vasculopathy is the major cause of late death in cardiac transplant&#xD;
      patients.&#xD;
&#xD;
      The different mechanisms of action of Everolimus and cyclosporine suppress immune function in&#xD;
      synergistic manner. Thus it is postulated that the use of Everolimus in combination with&#xD;
      cyclosporine permits a significant cyclosporine dose reduction without loss of&#xD;
      immunosuppressive activity in the clinical setting.&#xD;
&#xD;
      The aim of the present study is to evaluate the evolution of renal function after initiation&#xD;
      of Everolimus and minimalisation of CNI dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of renal function after initiation of Everolimus and minimalisation of CNI dose.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of major adverse cardiovascular events</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Rejection of Cardiac Transplant</condition>
  <arm_group>
    <arm_group_label>Everolimus, Immunosupression</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus and reduced dose CNI: reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.</description>
    <arm_group_label>Everolimus, Immunosupression</arm_group_label>
    <other_name>certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 year&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  6 months to 15 year after heart transplantation&#xD;
&#xD;
          -  Stable heart allograft function without rejection for at least 12 months&#xD;
&#xD;
          -  Same immunusuppressive drugs for at least 3 months&#xD;
&#xD;
          -  CNI based immunusuppression, with Cyclosporin levels C0 100-200 ng/ml FK levels of&#xD;
             5-10 ng/ml for preserved CNI levels.&#xD;
&#xD;
          -  Poor renal function: creatinine &gt; 1.5 mg%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected non-compliance&#xD;
&#xD;
          -  Intolerance to Everolimus&#xD;
&#xD;
          -  Life expectancy &lt; 1year&#xD;
&#xD;
          -  Proteinuria &gt; 1.5 g/24u/1.73m2&#xD;
&#xD;
          -  Previous sirolimus treatment&#xD;
&#xD;
          -  Patients who received any other investigational drug&#xD;
&#xD;
          -  Patients with platelet count &lt;50,000/mm³ before baseline.&#xD;
&#xD;
          -  Presence of severe hypercholesterolemia (≥350 mg/dL; ≥9 mmol/L) or&#xD;
             hypertriglyceridemia (≥750 mg/dL; ≥8.5 mmol/L)&#xD;
&#xD;
          -  Patients with an absolute neutrophil count of ≤ 1,500/mm3 or white blood cell count of&#xD;
             ≤ 4000/mm³ at baseline&#xD;
&#xD;
          -  Patients with a known hypersensitivity to similar drugs and to the components of the&#xD;
             formulations&#xD;
&#xD;
          -  Patients being treated with terfenadine, astemizole, or cisapride.&#xD;
&#xD;
          -  Patients who are treated with drugs strong inducers or inhibitors of cytochrome P450&#xD;
             3A4.&#xD;
&#xD;
          -  Patients with any past (within the past 5 years) or present malignancy (other than&#xD;
             excised basal cell carcinoma)&#xD;
&#xD;
          -  Patients with clinically significant systemic infection.&#xD;
&#xD;
          -  Existence of any surgical or medical condition, which in the opinion of the&#xD;
             investigator, might significantly alter the absorption, distribution, metabolism and&#xD;
             excretion of study medication, and/or the presence of severe diarrhea or active peptic&#xD;
             ulcer.&#xD;
&#xD;
          -  Females of childbearing potential who are planning to become pregnant, who are&#xD;
             pregnant and/or lactating, who are unwilling to use effective means of contraception.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tuvia Ben Gal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabin Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology Department, Rabin Medical Center</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Tuvia Ben Gal MD, Director of the heart failure unit</name_title>
    <organization>Cardiology department, Rabin Medical Center</organization>
  </responsible_party>
  <keyword>Renal function, heart transplant, everolimus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

